Literature DB >> 30930563

Outcomes of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension at a Single Center in Taiwan.

Yu-Jhou Chen1, Chien-Te Ho2, Feng-Chun Tsai3, Chia-Pin Lin2, Lung-An Hsu2, Chun-Li Wang2, Kuang-Tso Lee2, Wan-Jing Ho2.   

Abstract

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group IV pulmonary hypertension. This study aimed to report our institutional experience in managing CTEPH.
METHODS: We prospectively collected the data of 23 patients diagnosed with CTEPH between August 2001 and August 2017 in Linkou Chang Gung Memorial Hospital. Baseline characteristics including functional class (FC), 6-minute walk distance (6MWD), comorbidities, hematological and biochemical data, echocardiography, cardiac catheterization, and selective pulmonary angiography were recorded at diagnosis. All patients were referred to a cardiac surgeon for pulmonary endarterectomy (PEA) assessment.
RESULTS: The mean age at diagnosis was 48.4 ± 16.1 years. Nineteen patients (83%) underwent PEA with mean postoperative follow-up of 37.7 ± 42.8 months. The in-hospital mortality rate of PEA was 11%. The 1-, 2-, 3- and 5-year overall survival rates were 89%, 89%, 81%, and 50%, respectively. After 3 months of PEA, all patients had improvements in FC, 6MWD (from 326 ± 62 to 420 ± 63 m), B-type natriuretic peptide level (from 602 ± 599 to 268 ± 565 pg/mL), and systolic pulmonary artery pressure (from 79 ± 19 to 48 ± 19 mmHg). The patients with proximal disease (Jamieson type 1 or 2) had better survival than those with distal disease (Jamieson type 3 or 4), but there was no significant difference in mortality between FC III and IV. All of the four patients who did not undergo PEA survived for more than 3 years.
CONCLUSIONS: Significant improvements in symptoms, functional capacity, and hemodynamics were achieved in the CTEPH patients after PEA. However, the overall survival was still unsatisfactory.

Entities:  

Keywords:  Functional class; Jamieson classification; Pulmonary endarterectomy; Pulmonary hypertension; Pulmonary vascular disease

Year:  2019        PMID: 30930563      PMCID: PMC6434418          DOI: 10.6515/ACS.201903_35(2).20180904A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  38 in total

1.  Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease.

Authors:  Antonios P Vlahos; Jeffrey A Feinstein; Nelson B Schiller; Norman H Silverman
Journal:  J Am Soc Echocardiogr       Date:  2008-01-09       Impact factor: 5.251

2.  Is right ventricular systolic function reduced after cardiac surgery? A two- and three-dimensional echocardiographic study.

Authors:  Gloria Tamborini; Manuela Muratori; Denise Brusoni; Fabrizio Celeste; Francesco Maffessanti; Enrico G Caiani; Francesco Alamanni; Mauro Pepi
Journal:  Eur J Echocardiogr       Date:  2009-02-27

3.  New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure.

Authors:  Denis Chemla; Vincent Castelain; Marc Humbert; Jean-Louis Hébert; Gérald Simonneau; Yves Lecarpentier; Philippe Hervé
Journal:  Chest       Date:  2004-10       Impact factor: 9.410

4.  ABO(H) blood groups and vascular disease: a systematic review and meta-analysis.

Authors:  O Wu; N Bayoumi; M A Vickers; P Clark
Journal:  J Thromb Haemost       Date:  2007-10-25       Impact factor: 5.824

5.  Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy.

Authors:  Patricia A Thistlethwaite; Makato Mo; Michael M Madani; Reena Deutsch; Daniel Blanchard; David P Kapelanski; Stuart W Jamieson
Journal:  J Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 5.209

6.  Risk factors for chronic thromboembolic pulmonary hypertension.

Authors:  D Bonderman; H Wilkens; S Wakounig; H-J Schäfers; P Jansa; J Lindner; I Simkova; A M Martischnig; J Dudczak; R Sadushi; N Skoro-Sajer; W Klepetko; I M Lang
Journal:  Eur Respir J       Date:  2008-09-17       Impact factor: 16.671

7.  Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.

Authors:  M A Olman; J J Marsh; I M Lang; K M Moser; B R Binder; R R Schleef
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

8.  Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.

Authors:  Timothy A Morris; James J Marsh; Peter G Chiles; William R Auger; Peter F Fedullo; Virgil L Woods
Journal:  Am J Respir Crit Care Med       Date:  2006-03-02       Impact factor: 21.405

9.  Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.

Authors:  Stuart W Jamieson; David P Kapelanski; Naohide Sakakibara; Gerard R Manecke; Patricia A Thistlethwaite; Kim M Kerr; Richard N Channick; Peter F Fedullo; William R Auger
Journal:  Ann Thorac Surg       Date:  2003-11       Impact factor: 4.330

10.  High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.

Authors:  Diana Bonderman; Peter L Turecek; Johannes Jakowitsch; Ansgar Weltermann; Christopher Adlbrecht; Barbara Schneider; Meinhard Kneussl; Lewis J Rubin; Paul A Kyrle; Walter Klepetko; Gerald Maurer; Irene M Lang
Journal:  Thromb Haemost       Date:  2003-09       Impact factor: 5.249

View more
  5 in total

1.  Application and Comparison of Different Prognostic Scoring Systems in Patients Who Underwent Cardiologist-Managed Percutaneous Cardiopulmonary Support.

Authors:  Shih-Chieh Chien; Wei-Ren Lan; Shu-Hao Wu; Chen-Yen Chien; Yu-Shan Chien; Chi-In Lo; Cheng-Ting Tsai; Chun-Yen Chen
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

2.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

Review 3.  Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Liyan Zhang; Yuping Bai; Peijing Yan; Tingting He; Bin Liu; Shanlian Wu; Zhen Qian; Changtian Li; Yunshan Cao; Min Zhang
Journal:  Heart Fail Rev       Date:  2021-02-05       Impact factor: 4.214

4.  Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Ling-Wei Chen; Ssu-Yuan Chen; Hsao-Hsun Hsu; Yen-Wen Wu; Yu-Mei Lai; Meng-Yueh Chien
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

5.  Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Cheng-Hsuan Tsai; Cho-Kai Wu; Ping-Hung Kuo; Hsao-Hsun Hsu; Zheng-Wei Chen; Juey-Jen Hwang; Chi-Lun Ko; Yu-Sen Huang; Yen-Hung Lin
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.